Purpose: To compare the replacement of every drug with latanoprost 0.005% once a day in glaucomatous eyes with poorly controlled intraocular pressure upon combination therapy, versus addition of latanoprost to the pre-existing treatment. Patients and Methods: Study design: prospective, investigator-masked, two-center, randomized clinical trial lasting 3 months. Eligibility criteria: open-angle glaucoma; IOP >= 21 mm Hg upon the combination of a non-selective beta-blocker with pilocarpine or dorzolamide or both; no previous bulbar surgery; and prior glaucoma therapy lasting at least 2 years. Two treatment arms: (1) addition of latanoprost 0.005% QD to the pre-existing therapy [group A]; (2) substitution with latanoprost alone [group B]. Results: One hundred thirty-six eyes (68 eyes/treatment group) were randomized according to intraocular pressure level and the number of adjunctive medications to beta blocker. Both treatments provided a significant IOP decrease over baseline (from 23.5 ± 1.4 to 19.7 ± 1.9 mm Hg in group A, (P < 0.001); from 23.2 ± 1.3 to 20.1 ± 2.2 mm Hg in group B (P < 0.001), paired Student t test). At the end of the follow-up period, group A showed a higher number of intraocular readings less than or equal to 18 mm Hg than group B (42.6% vs. 30.8%; Fisher exact test:P = 0.018). Conclusions: In eyes showing an intraocular pressure greater than 21 mm Hg upon combination therapy, the substitution of the pre-existing treatment with latanoprost can provide a significant IOP decrease. However, adding latanoprost to the pre-existing therapy is more likely to achieve a target intraocular pressure less than or equal to 18 mm Hg.
Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications : a two-center randomized prospective trial / S.A. Gandolfi, L. Rossetti, L. Cimino, P. Mora, M. Tardini, N. Orzalesi. - In: JOURNAL OF GLAUCOMA. - ISSN 1057-0829. - 12:4(2003 Aug), pp. 347-353.
Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications : a two-center randomized prospective trial
L. RossettiSecondo
;N. OrzalesiUltimo
2003
Abstract
Purpose: To compare the replacement of every drug with latanoprost 0.005% once a day in glaucomatous eyes with poorly controlled intraocular pressure upon combination therapy, versus addition of latanoprost to the pre-existing treatment. Patients and Methods: Study design: prospective, investigator-masked, two-center, randomized clinical trial lasting 3 months. Eligibility criteria: open-angle glaucoma; IOP >= 21 mm Hg upon the combination of a non-selective beta-blocker with pilocarpine or dorzolamide or both; no previous bulbar surgery; and prior glaucoma therapy lasting at least 2 years. Two treatment arms: (1) addition of latanoprost 0.005% QD to the pre-existing therapy [group A]; (2) substitution with latanoprost alone [group B]. Results: One hundred thirty-six eyes (68 eyes/treatment group) were randomized according to intraocular pressure level and the number of adjunctive medications to beta blocker. Both treatments provided a significant IOP decrease over baseline (from 23.5 ± 1.4 to 19.7 ± 1.9 mm Hg in group A, (P < 0.001); from 23.2 ± 1.3 to 20.1 ± 2.2 mm Hg in group B (P < 0.001), paired Student t test). At the end of the follow-up period, group A showed a higher number of intraocular readings less than or equal to 18 mm Hg than group B (42.6% vs. 30.8%; Fisher exact test:P = 0.018). Conclusions: In eyes showing an intraocular pressure greater than 21 mm Hg upon combination therapy, the substitution of the pre-existing treatment with latanoprost can provide a significant IOP decrease. However, adding latanoprost to the pre-existing therapy is more likely to achieve a target intraocular pressure less than or equal to 18 mm Hg.File | Dimensione | Formato | |
---|---|---|---|
00061198-200308000-00009.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
444.17 kB
Formato
Adobe PDF
|
444.17 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.